ribosomal protein L12 pseudogene 12Genealiases: RPL12L3 · RPL12_16_1689 · dJ999L4.1
Q-omics provides the consensus-scored RPL12P12 profile across patient tissues and cancer cell-line models. RPL12P12 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, RPL12P12 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, RPL12P12 RNA expression shows 11,923 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LUSC, KIRC, and TGCT as cancer lineages where RPL12P12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL12P12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL12P12 survival associations across molecular data types. RPL12P12 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL12P12 RNA expression–survival associations across cancer types. High RPL12P12 expression shows unfavorable associations in SKCM and ACC, but favorable associations in LUSC, THCA, THYM and KIRC. The LUSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUSC as the clearest survival context for RPL12P12 RNA expression.
This table summarizes RPL12P12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL12P12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL12P12 shows lower tumor expression in KICH and higher tumor expression in KIRC, COAD, THCA, HNSC and LIHC. The KIRC box plot shows higher RPL12P12 RNA expression in tumor versus normal tissue (log2 FC = +0.591, t-test p < 0.001).
This table shows molecular features associated with RPL12P12 in patient tissues and cancer cell lines. In patient samples, RPL12P12 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
